MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$2,978M
Free Cash flow
$3,416M
Unit: Million (M) dollars
Positive Cash Flow Breakdown
Premium and trade receivables
Accounts payable and accrued exp...
Sales and maturities of investme...
Others
Negative Cash Flow Breakdown
Purchases of investments
Medical claims liabilities
Other assets
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net earnings
1,087
1,539
-1,100
-6,632
Depreciation and amortization
300
300
329
317
Stock compensation expense
59
67
58
52
Impairment
0
-
513
6,743
(gain) loss on debt extinguishment
6
-5
1
-
Deferred income taxes
19
-53
-73
129
Loss on divestitures
0
0
12
0
Premium and trade receivables
-1,347
1,353
-4,818
1,537
Other assets
300
188
-15
-298
Medical claims liabilities
-363
95
-840
1,367
Unearned revenue
-247
217
85
-26
Accounts payable and accrued expenses
1,344
2,905
-3,338
2,472
Other long-term liabilities
313
849
-84
-1,819
Other operating activities, net
37
-17
67
8
Net cash provided by operating activities
3,590
4,366
437
1,356
Capital expenditures
174
200
213
211
Purchases of investments
1,341
987
776
172
Sales and maturities of investments
1,162
1,276
1,649
1,623
Divestiture proceeds, net of divested cash
-
-
0
0
Net cash (used in) investing activities
-353
89
660
1,240
Proceeds from long-term debt
0
0
0
0
Payments and repurchases of long-term debt
258
1,046
187
1
Common stock repurchases
4
29
2
0
Proceeds from common stock issuances
8
10
8
11
Purchase of noncontrolling interest
-
-
0
19
Other financing activities, net
-5
2
-6
-1
Net cash (used in) financing activities
-259
-1,063
-187
-10
Effect of exchange rate changes on cash, cash equivalents and restricted cash
-
-
0
0
Net increase in cash, cash equivalents and restricted cash and cash equivalents
2,978
3,392
910
2,586
Cash and cash equivalents reclassified from held for sale
-
4
-
0
Cash, cash equivalents and restricted cash and cash equivalents, beginning of period
-
14,599
-
14,887
Cash, cash equivalents and restricted cash and cash equivalents, end of period
-
21,353
-
17,185
Page 1
Unit: Million (M) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Premium and trade
receivables
-$1,347M
(-52.55%↓ Y/Y)
Accounts payable and
accrued expenses
$1,344M
(479.66%↑ Y/Y)
Net earnings
$1,087M
(519.69%↑ Y/Y)
Other long-term
liabilities
$313M
(-69.99%↓ Y/Y)
Depreciation and
amortization
$300M
(-4.76%↓ Y/Y)
Stock compensation
expense
$59M
(68.57%↑ Y/Y)
Other operating
activities, net
$37M
Deferred income taxes
$19M
(121.35%↑ Y/Y)
Net cash provided by
operating activities
$3,590M
(101.12%↑ Y/Y)
Canceled cashflow
$916M
Net increase in
cash, cash...
$2,978M
(1134.03%↑ Y/Y)
Canceled cashflow
$612M
Medical claims
liabilities
-$363M
(-276.21%↓ Y/Y)
Other assets
$300M
(338.10%↑ Y/Y)
Unearned revenue
-$247M
(-32.09%↓ Y/Y)
(gain) loss on debt
extinguishment
$6M
Sales and maturities
of investments
$1,162M
(-8.65%↓ Y/Y)
Proceeds from common
stock issuances
$8M
(0.00%↑ Y/Y)
Net cash (used in)
investing activities
-$353M
(60.73%↑ Y/Y)
Net cash (used in)
financing activities
-$259M
(77.94%↑ Y/Y)
Canceled cashflow
$1,162M
Canceled cashflow
$8M
Purchases of investments
$1,341M
(-31.69%↓ Y/Y)
Payments and repurchases
of long-term debt
$258M
(-65.55%↓ Y/Y)
Other financing
activities, net
-$5M
(-400.00%↓ Y/Y)
Capital expenditures
$174M
(-16.35%↓ Y/Y)
Common stock
repurchases
$4M
(-99.07%↓ Y/Y)
Buy us a coffee
centene_logo_white-svg
CENTENE CORP (CNC)
centene_logo_white-svg
CENTENE CORP (CNC)
Show more